Novaremed Secures US $50 Million Capital Commitment from Global Emerging Markets
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private, alternative investment group for a US $50 million capital commitment.
Under the agreement, GEM commits to provide Novaremed with a share subscription facility of up to US $50 million for a 36-month term following the public listing of the company’s shares. Novaremed will control the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. Concurrent with a public listing of Novaremed shares, the company will issue warrants to GEM to purchase shares of Novaremed.
Subject to the funding becoming available, the proceeds from this financing will be used to progress the clinical development of Novaremed’s lead product, NRD135S.E1, an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy (PDPN).
“We are very pleased about this financial arrangement with GEM,” said Isaac Kobrin, M.D., Executive Chairman of the Board of Novaremed. “This funding agreement with GEM will help us, upon the company’s public listing, to advance our highly innovative lead product that we are developing for the non-opioid treatment of patients affected by diabetes-related chronic neuropathic pain. The ongoing opioid crisis has increased the high unmet medical need for novel treatments, which can control chronic pain without inducing addiction, dependence and abuse.”
About Painful Diabetic Peripheral Neuropathy (PDPN)
Peripheral nerve injury from various etiologies (e.g., diabetic peripheral neuropathy, postherpetic neuralgia, neuropathy due to cancer or trauma) may result in chronic and severe intractable neuropathic pain. PDPN is one of the most frequent complications of diabetes. Up to 20% of patients with PDPN experience chronic, debilitating neuropathic pain that substantially impairs quality of life. Many of the currently available drugs for the treatment of PDPN have limited efficacy and are often not well tolerated due to multiple side effects, including those to central nervous system.
The rapidly increasing prevalence of diabetes and of PDPN as well as the limitations of the available therapies makes the treatment of PDPN a condition of high unmet medical need.
NRD135S.E1 (or NRD.E1) is a new chemical entity, that is orally available and being developed for the treatment of PDPN. The mechanism of action of NRD.E1 is different to that of approved pain therapies as the investigational drug does not bind to or interact with receptors associated with pain nor does it bind to opioid receptors.
Completed clinical studies with NRD.E1 include three Phase I studies (single and multiple ascending dose studies and food-effect study). The Phase IIa Proof of Concept study (ClinicalTrials.gov Identifier: NCT02345291) was a 3-week, dose finding, placebo-controlled, randomized, multi-center study. The study was conducted in 88 patients with moderate to severe PDPN and compared three doses (10mg, 40mg and 150 mg/day) of NRD.E1 to placebo. Results showed a clinically relevant, dose-related pain reduction; NRD.E1 was well tolerated at all tested doses.
Novaremed has an open IND for NRD.E1 to conduct a 12-week Phase II study in 120 patients with moderate to severe PDPN in the US. The study compares efficacy, safety and tolerability of one dose of NRD.E1 to placebo. The primary objective of the study is to demonstrate that NRD.E1 is superior to placebo in relieving neuropathic pain associated with PDPN. The primary endpoint is the change from the baseline to Week 12 in the weekly mean of daily pain, as measured by an 11-point Numeric Rating Scale (NRS). The main secondary objectives of the study are to evaluate (i) the safety and tolerability of NRD.E1, (ii) the presence of withdrawal symptoms after abrupt drug interruption, and (iii) the effect of NRD.E1 on insomnia and quality-of-life indicators.
In December 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to NRD.E1 for the treatment of PDPN.
Novaremed Ltd, a wholly owned subsidiary of Novaremed AG was founded in 2008 in Israel and Novaremed AG was founded in 2017 in Switzerland. Novaremed aims to become a leader in the discovery and development of innovative treatment options for chronic pain and currently is developing NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action for the treatment of PDPN.
About the GEM Group
Global Emerging Markets (“GEM”) is a $3.4 billion, alternative investment group with operations in Paris, New York, and Los Angeles. GEM manages a diverse set of investment vehicles focused on emerging markets and has completed over 400 transactions in 70 countries. Each investment vehicle has a different degree of operational control, risk-adjusted return, and liquidity profile. The family of funds and investment vehicles provide GEM and its partners with exposure to: Small-Mid Cap Management Buyouts, Private Investments in Public Equities and select venture investments. For more information: www.gemny.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PMI Launches Free, Online Course and Tool Kit to Help Changemakers Jumpstart Project Success in Just 45 Minutes2.3.2021 19:00:00 EET | Press release
Project Management Institute (PMI), the world's leading association for project professionals and changemakers, today announced the launch of KICKOFF, a new, free online course and tool kit to help introduce anyone doing project-based work to the best practices and tools needed to effectively manage projects from ideation to execution. Much of the working world revolves around projects, which have become more complex than ever due to global Megatrends, including COVID-19, climate change, and more. The need for changemakers, regardless of industry or position level, to be well-versed in the principles of project management in order to help drive results, has never been greater. KICKOFF is the ideal solution for those who are new to doing project-based work and would benefit from learning project management skills to help successfully navigate the process from idea to launch and execution. The course is packed with digestible content, downloadable templates, a glossary of key terms, and
Xendit Raises US$64.6 Million Series B Led by Accel to Scale Its Digital Payments Infrastructure Ushering in a New Era of Economic Security and Reliability in Southeast Asia2.3.2021 18:08:00 EET | Press release
Xendit, the fastest growing digital payments infrastructure for Southeast Asia, announces it has raised US$64.6 million in a Series B round led by Accel to deliver more secure and reliable economic success in the region. Altogether, the company has raised $88 million in funding. Amid Southeast Asia’s rapid digital transformation, Xendit is quickly bolstering businesses of all sizes, processing more than 65 million transactions with US$6.5 billion in payment value annually. “Southeast Asia is a massively complex region, with Indonesia having 17,000 different islands alone—not to mention the region’s regulatory and technological challenges. Trying to build the businesses of tomorrow on yesterday's infrastructure is holding Southeast Asia’s businesses back,” said Moses Lo, CEO and Co-Founder. “This latest investment will enable Xendit to scale our digital payments infrastructure quickly and provide millions of small and medium-sized businesses across Southeast Asia with an on-ramp to the
Andersen Global Initiates Expansion Into Bermuda2.3.2021 17:30:00 EET | Press release
Andersen Global establishes a presence in Bermuda through a Collaboration Agreement with Hamilton-based law firm Alexanders, Barristers & Attorneys, adding additional coverage to its global platform. Founded in 2005, Alexanders, Barristers & Attorneys is a law firm with a primary focus on corporate and trust laws. The firm provides services to corporate clients and high net worth individuals, which complements the U.S. member firm’s practice and the global organization’s ability to meet clients’ cross-border needs in Australia, Canada, Africa, the United Kingdom and globally through its member firms and collaborating firms. Additionally, the firm specializes in intellectual property registration and law, investment fund formation and law, insurance company formation and law, and admiralty and maritime law. “Our top priority is delivering best-in-class solutions to our clients locally and abroad, and our ability to do that has been and continues to be a key contributor to our firm’s suc
BORN Expands With Alkeon B2B Market Network Platform Transforming Commercial Models, Starting With the Trade Show Industry2.3.2021 17:12:00 EET | Press release
BORN, announces the expansion of innovative B2B subsidiary Alkeon, the world's first global SaaS market-network combining content, community, and commerce to connect buyers and sellers through a best-in-class platform, powered by machine learning. The 2020 pandemic generated a tremendous and immediate need for companies of all categories to pivot at a moment’s notice, with over 10,000 global trade shows completely upended due to cancellations of physical events. BORN, a purpose driven lifestyle company dedicated to reimagining the discovery, transaction and connection of the B2B and B2C communities, found an opportune moment to quickly scale and enhance their technology solutions. The company formally established Alkeon, an enterprise dedicated to supporting the needs of companies who are adapting to the current and future landscapes and need the right partner to support them through the process. Combining aesthetic and function to create designed technology, Alkeon is a market-network
South Africa and France Lead the Way in Public and Private Sector Gender Diversity, Latest Research by Kearney Reveals2.3.2021 17:00:00 EET | Press release
The latest ‘Gender Equality Report’ from Kearney has revealed progress in the representation of women in both public and private sectors, but the figures still don’t show parity. Ahead of International Women’s Day, the analysis provides insight into the progress of gender diversity in private and public sectors across nine countries – the United States, United Kingdom, Australia, India, France, Spain, Germany, South Africa and Singapore. The annual report revealed that France was number one for representation in the private sector with women comprising nearly 44% (43.8%) of board members on average, however only 2% of these women held top board positions. The UK (36%) and Australia (34%) also scored highly for representation of women on boards. The average for board level representation of women is 29.9% - not even one in three. % Female board level representation by country France 43.8% UK 36.0% Australia 34.0% Germany 32.5% Spain 29.8% US 29.8% South Africa 28.5% Singapore 17.3% Indi
beqom Announces beqom FlexFS, a Compensation Management Solution Dedicated to Financial Services2.3.2021 17:00:00 EET | Press release
beqom, provider of cloud-based compensation management software, today announced the launch of beqom FlexFS, a solution designed specifically for the financial services (FS) industry. “Financial services compensation is unique,” says Vismay Gada, Head of North America and Global Financial Services at beqom. “First there is a broad spectrum of financial services companies—retail banking, investment banking, asset management, hedge funds, insurance, private equity, and so on. That means that rewards and deferred compensation structures have many specialized needs across the industry. And, companies in each segment have to deal with different regulations that impact compensation treatment, which has its own unique challenges. Our FS customers have come to us to help them address complex compensation requirements that are beyond the scope of what their core HR systems can handle.” “We usually see a lot of our FS companies use Excel or Access databases to augment the limitations of core HR
Kymeta and Blue Edge Global Strategic Partnership Delivers Real World SATCOM Field Training with Military Trained Specialists2.3.2021 17:00:00 EET | Press release
Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today a new premier training partnership with Blue Edge Global, a privately owned and operated, certified Service-Disabled Veteran Owned Small Business. The partnership is designed to provide instructor-led responsive training solutions for land, air, sea, and space domains where uninterrupted communications are required to enable high risk missions, first responder arrive-ready solutions and where natural or other disasters require immediate logistical support. Together, Kymeta and Blue Edge Global will offer downrange training with a team of military SATCOM specialists to the Department of Defense (DoD), Ministry of Defense (MoD) and Emergency Services teams globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005134/en/ Military specialist attends advanced SATCOM training. (Photo: Business Wire) The collaboration with Blue Ed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom